Clarivate Epidemiology’s coverage of systemic lupus erythematosus (SLE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
Characterized by high incidence and long treatment durations, the breast cancer therapy market represents substantial commercial opportunity for drug developers. CDK4/6 inhibitors (Pfizer’s…
The treatment landscape for COVID-19 continues to evolve rapidly. Even with vaccines having become available in the markets under study, intense ongoing research has also focused on approaches…
Clarivate Epidemiology’s coverage of epilepsy comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of epilepsy for each country, as…
Clarivate Epidemiology’s coverage of epilepsy comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of epilepsy for each country, as…
DRG Epidemiology's coverage of non-alcoholic fatty liver disease (NAFLD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence…
DRG Epidemiology's coverage of non-alcoholic fatty liver disease (NAFLD) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the…
DRG Epidemiology’s coverage of non-alcoholic fatty liver disease (NAFLD) comprises epidemiological estimates of key patient populations in 45 countries. We report the prevalence of NAFLD for each…
DRG Epidemiology's coverage of non-alcoholic fatty liver disease (NAFLD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence…
DRG Epidemiology's coverage of non-alcoholic fatty liver disease (NAFLD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence…
DRG Epidemiology's coverage of non-alcoholic fatty liver disease (NAFLD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence…
Cystic fibrosis (CF) is a genetic disease caused by any one of the more than 2,000 mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. CFTR mutations lead…
Biosimilars of erythropoiesis-stimulating agents (ESAs) entered the European market a decade ago, but the FDA did not approve the first ESA biosimilar—Retacrit—until June 2018; it launched in…
Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity…
Metastatic non-small-cell lung cancer (NSCLC) is a highly segmented indication defined by tumor histology and mutational status. Metastatic nonsquamous NSCLC patients are routinely tested for the…